Pharmacoepidemiology, Third Edition

Copyright © 2000 John Wiley & Sons, Ltd

Pharmacoepidemiology, Third Edition

Editor(s): Brian L. Strom

Published Online: 24 APR 2002

Print ISBN: 9780471899259

Online ISBN: 9780470842553

DOI: 10.1002/0470842555

Table of contents

    1. You have free access to this content
      Front Matter and Index (pages i–xxiii)

  2. Part I: Introduction

    1. Chapter 1

      What is Pharmacoepidemiology? (pages 1–15)

      Brian L. Strom

    2. Chapter 2

      Study Designs Available for Pharmacoepidemiology Studies (pages 17–29)

      Brian L. Strom

    3. Chapter 3

      Sample Size Considerations for Pharmacoepidemiology Studies (pages 31–39)

      Brian L. Strom

    4. Chapter 4

      Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies (pages 41–62)

      Patricia McGettigan, David A. Henry and Sean Hennessy

    5. Chapter 5

      When Should One Perform Pharmacoepidemiology Studies? (pages 63–71)

      Brian L. Strom

  3. Part II: Perspectives on Pharmacoepidemiology

    1. Chapter 6

      The Public Health, the University, and Pharmacoepidemiology (pages 73–89)

      Paul D. Stolley and Joan-Ramon Laporte

    2. Chapter 7

      A View From Industry (pages 91–108)

      Dale B. Glasser and Gretchen S. Dieck

    3. Chapter 8

      A View From Regulatory Agencies (pages 109–124)

      David J. Graham, Patrick C. Waller and Xavier Kurz

    4. Chapter 9

      A View From a US Courtroom (pages 125–148)

      James R. Ruger and Sidney H. Willig

  4. Part III: Systems available for Pharmacoepidemiology Studies

    1. Chapter 10

      Spontaneous Reporting in the United States (pages 149–174)

      Dianne L. Kennedy, Stephen A. Goldman and Ralph B. Lillie

    2. Chapter 11

      Spontaneous Reporting Systems Outside the US (pages 175–192)

      Bengt-Erik Wiholm, Sten Olsson, Nicholas Moore and Patrick Waller

    3. Chapter 12

      Intensive Hospital-based Cohort Studies (pages 193–207)

      Keith Beard and David H. Lawson

    4. Chapter 13

      Case–Control Surveillance (pages 209–230)

      Samuel Shapiro

    5. Chapter 14

      Prescription-event Monitoring (pages 231–246)

      Ronald D. Mann

    6. Chapter 15

      Group Health Cooperative of Puget Sound (pages 247–262)

      Kathleen W. Saunders, Robert L. Davis and Andy Stergachis

    7. Chapter 16

      Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division (pages 263–283)

      Gary D. Friedman, Laurel A. Habel, Myde Boles and Bentson H. McFarland

    8. Chapter 17

      Harvard Pilgrim Health Care/Harvard Vanguard Medical Associates (pages 285–293)

      K. Arnold Chan and Richard Platt

    9. Chapter 18

      UnitedHealth Group (pages 295–305)

      Deborah Shatin, Carole Drinkard and Andy Stergachis

    10. Chapter 19

      Medicaid Databases (pages 307–324)

      Jeffrey L. Carson, Wayne A. Ray and Brian L. Strom

    11. Chapter 20

      Health Databases in Saskatchewan (pages 325–345)

      Winanne Downey, Patricia Beck, Mary McNutt, Mary Rose Stang, William Osei and Jim Nichol

    12. Chapter 21

      Automated Pharmacy Record Linkage in The Netherlands (pages 347–360)

      Hubert G. Leufkens and John Urquhart

    13. Chapter 22

      The Tayside Medicines Monitoring Unit (MEMO) (pages 361–374)

      Josie M.M. Evans and Thomas M. Macdonald

    14. Chapter 23

      The UK General Practice Research Database (pages 375–385)

      Luis Alberto García Rodríguez, Susanne Pérez-Gutthann and Susan Jick

    15. Chapter 24

      Other Approaches to Pharmacoepidemiology Studies (pages 387–399)

      Brian L. Strom

    16. Chapter 25

      How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives (pages 401–413)

      Brian L. Strom

  5. Part IV: Selected Special Applications and Methodological Issues in Pharmacoepidemiology

    1. Chapter 26

      Bioethical Issues in Pharmacoepidemiology Research (pages 415–431)

      David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur Caplan

    2. Chapter 27

      National Medicinal Drug Policies: their Relationship to Pharmacoepidemiology (pages 433–447)

      Suzanne Hill and David A. Henry

    3. Chapter 28

      Premarketing Applications of Pharmacoepidemiology (pages 449–462)

      Harry A. Guess

    4. Chapter 29

      Studies of Drug Utilization (pages 463–481)

      David Lee and Ulf Bergman

    5. Chapter 30

      Evaluating and Improving Physician Prescribing (pages 483–503)

      Stephen B. Soumerai, Sumit Majumdar and Helene L. Lipton

    6. Chapter 31

      Drug Utilization Review (pages 505–523)

      Sean Hennessy, Brian L. Strom, Helene L. Lipton and Stephen B. Soumerai

    7. Chapter 32

      Determining Causation from Case Reports (pages 525–538)

      Judith K. Jones

    8. Chapter 33

      The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies (pages 539–552)

      Samuel M. Lesko and Allen A. Mitchell

    9. Chapter 34

      The Use of Pharmacoepidemiology to Study Beneficial Drug Effects (pages 553–572)

      Brian L. Strom and Kenneth L. Melmon

    10. Chapter 35

      Pharmacoeconomics: Economic Evaluation of Pharmaceuticals (pages 573–601)

      Kevin A. Schulman, Henry Glick, Daniel Polsky and John M. Eisenberg

    11. Chapter 36

      Using Quality of Life Measurements in Pharmacoepidemiology Research (pages 603–613)

      Gordon H. Guyatt and Roman Jaeschke

    12. Chapter 37

      N-of-1 Randomized Clinical Trials in Pharmacoepidemiology (pages 615–631)

      Gordon H. Guyatt, Roman Jaeschke and Robin Roberts

    13. Chapter 38

      The Use of Meta-analysis in Pharmacoepidemiology (pages 633–659)

      Jesse A. Berlin

    14. Chapter 39

      Validity of Pharmacoepidemiology Drug and Diagnosis Data (pages 661–705)

      Suzanne L. West, Brian L. Strom and Charles Poole

    15. Chapter 40

      Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety (pages 707–732)

      Robert T. Chen

    16. Chapter 41

      Special Methodological Issues in Pharmacoepidemiology Studies of Devices (pages 733–747)

      Roselie A. Bright

    17. Chapter 42

      Special Considerations in Studies of Drug-induced Birth Defects (pages 749–763)

      Allen A. Mitchell

    18. Chapter 43

      Bias and Confounding in Pharmacoepidemiology (pages 765–784)

      Jean-Paul Collet and Jean-François Boivin

    19. Chapter 44

      Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis (pages 785–805)

      Samy Suissa

  6. Part V: Conclusion

    1. Chapter 45

      The Future of Pharmacoepidemiology (pages 807–816)

      Brian L. Strom

    1. You have free access to this content
      Appendix A: Sample Size Tables (pages 817–850)

    1. You have free access to this content
      Appendix B: Glossary (pages 851–858)

SEARCH